CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Option exercise | +2,708 | $13.09 | $35K | 25,856 |
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Option exercise | +1,000 | $19.50 | $20K | 26,856 |
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Option exercise | +958 | $22.00 | $21K | 27,814 |
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Option exercise | +471 | $35.80 | $17K | 28,285 |
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Sale | −5,637 | $50.00 | $282K | 22,648 |
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −471 | 39,979 | ||
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −958 | 21,561 | ||
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −1,000 | 12,378 | ||
| 2020-02-05 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −2,708 | 0 | ||
| 2020-02-05 | Vasista Vittal Chief Financial Officer | Sale | −300 | $50.00 | $15K | 222,021 |
| 2020-02-05 | HAYDEN DONALD J JR Director | Option exercise | +2,000 | $0.85 | $2K | 2,000 |
| 2020-02-05 | HAYDEN DONALD J JR Director | Sale | −2,000 | $50.00 | $100K | 0 |
| 2020-02-05 | HAYDEN DONALD J JR Director | Option exercise · Stock Option (Right to Buy) | −2,000 | 153,900 | ||
| 2020-01-17 | Simpson Curran SVP, Product Development & CTO | Option exercise | +1,622 | $19.50 | $32K | 25,570 |
| 2020-01-17 | Simpson Curran SVP, Product Development & CTO | Option exercise | +2,700 | $22.00 | $59K | 28,270 |
| 2020-01-17 | Simpson Curran SVP, Product Development & CTO | Option exercise | +800 | $35.80 | $29K | 29,070 |
| 2020-01-17 | Simpson Curran SVP, Product Development & CTO | Sale | −5,922 | $50.00 | $296K | 23,148 |
| 2020-01-17 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −800 | 40,450 | ||
| 2020-01-17 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −2,700 | 22,519 | ||
| 2020-01-17 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −1,622 | 13,378 |
Page 24 of 25 · 494 trades